drugset / Trial / NCT02292290

Trial for People With Established Type 2 Diabetes During Ramadan

NCT02292290

RandomizedParallel-groupOpen-labelTreatment

Summary

Dual therapy with metformin and Liraglutide is more effective at helping people with established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no severe hypoglycaemic events.

Timeline

Start
2011-04
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.2 mg
Comparator Pioglitazone Small molecule